biotech / news / / Devdiscourse
FDA proposes to exclude weight-loss drugs of Novo Nordisk and Eli Lilly from critical compounding list.
The FDA proposes to exclude Novo Nordisk and Eli Lilly weight-loss drugs from the 503B compounding list.
KEY POINTS
- This exclusion targets unauthorized compounded versions that affect sales of Wegovy, Ozempic, Zepbound, and Mounjaro.
- Novo Nordisk and Eli Lilly stocks surged by nearly 6% and over 10% respectively after the announcement.
- The FDA stated there is no clinical need for outsourcing facilities to compound these active ingredients.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →